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Increased ICAM-1 Expression Causes Endothelial Cell
Leakiness, Cytoskeletal Reorganization and
Junctional Alterations
Paul R. Clark1,2, Thomas D. Manes2,3, Jordan S. Pober1,2,3,4, Martin S. Kluger1,2
Tumor necrosis factor (TNF)-induced ICAM-1 in endothelial cells (EC) promotes leukocyte adhesion. Here we
report that ICAM-1 also effects EC barrier function. Control- or E-selectin-transduced human dermal
microvascular EC (HDMEC) form a barrier to flux of proteins and to passage of current (measured as
transendothelial electrical resistance or TEER). HDMEC transduced with ICAM-1 at levels comparable to that
induced by TNF show reduced TEER, but do so without overtly changing their cell junctions, cell shape, or
cytoskeleton organization. Higher levels of ICAM-1 further reduce TEER, increase F/G-actin ratios, rearrange the
actin cytoskeleton to cause cell elongation, and alter junctional zona occludens 1 and vascular endothelial-
cadherin staining. Transducing with ICAM-1 lacking an intracellular region also reduces TEER. TNF-induced
changes in TEER and shape follow a similar time course as ICAM-1 induction; however, the fall in TEER occurs at
lower TNF concentrations. Inhibiting NF-kB activation blocks ICAM-1 induction; TEER reduction, and shape
change. Specific small-interfering RNA knockdown of ICAM-1 partially inhibits TNF-induced shape change. We
conclude that moderately elevated ICAM-1 expression reduces EC barrier function and that expressing higher
levels of ICAM-1 affects cell junctions and the cytoskeleton. Induction of ICAM-1 may contribute to but does
not fully account for TNF-induced vascular leak and EC shape change.
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INTRODUCTION
Acute inflammation is characterized by a number of changes
in local microvessels, including increased leakiness to plasma
proteins and increased adhesion of circulating leukocytes to
the endothelial cell (EC) lumenal surface (Pober and Cotran,
1991). Plasma protein extravasation is responsible for the
classical inflammatory sign of ‘‘tumor’’, commonly referred
to in skin as edema or induration, and serves to create a
provisional matrix within the tissue that can support
leukocyte diapedesis. Vascular leakiness may sometimes
become more widespread, involving one or more organs, for
example in settings of acute respiratory distress syndrome or
in systemic sepsis (Crowley, 1996; Groeneveld, 2002). The
early changes underlying vascular leakiness have been
attributed to concomitant alterations in EC shape and in cell
junctions, described as ‘‘retraction’’ or ‘‘contraction’’, or
viewed as inter-endothelial gap formation, respectively
(Majno and Palade, 1961; Majno et al., 1969; Wysolmerski
and Lagunoff, 1990; McDonald et al., 1999). These
morphological changes represent a maximal cytokine re-
sponse, and protein extravasation may be initiated by more
subtle alterations in the endothelial lining.
Leukocyte adhesion involves the transcription and expres-
sion of new surface proteins (adhesion molecules) on EC that
bind to counter-receptors on circulating leukocytes (von
Andrian and Mackay, 2000; Kluger, 2004). Many of these
adhesion molecules, including ICAM-1; (CD54) and E-
selectin (E-sel) (CD62E), are induced by tumor necrosis factor
(TNF; Pober et al., 1986b; Detmar et al., 1990; Richard et al.,
1998). Although the regulation of expression of various
adhesion molecules differ in detail, all depend upon the
transcription factor NF-kB, which is activated by TNF or other
proinflammatory cytokines (Collins et al., 1995). Intradermal
injection of TNF causes adhesion molecule expression and
local extravasation of leukocytes (Munro et al., 1989). TNF is
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also sufficient to produce vascular leak in vivo, for example
during cytokine-based immunotherapy (Cotran et al., 1988;
Lo et al., 1992; Dubinett et al., 1994; Thom et al., 1995). In
cell culture, TNF causes EC to undergo cytoskeletal and
junctional rearrangements and shape changes (Stolpen et al.,
1986; Blum et al., 1997). In particular, actin filaments,
concentrated along cell–cell junctions in resting cells, may
reorganize as thickened bands or as centrally distributed
stress fibers (Stolpen et al., 1986; Wojciak-Stothard et al.,
1998). These TNF-induced cytoskeletal changes have been
linked to an increase in filamentous (F-) and a simultaneous
decrease in globular (G-) actin content (Wojciak-Stothard
et al., 1998; Nwariaku et al., 2003). However, the mechan-
ism of such responses to TNF is less well understood than is
induction of adhesion molecules. In the present report, we
explore the hypothesis that vascular leakiness is mechan-
istically coupled to adhesion molecule induction, especially
of ICAM-1. We propose this concept based on the observa-
tions that inflammation-associated leakiness is reduced in
ICAM-1/ mice (Sligh et al., 1993; Xu et al., 1994) and that
the intracellular cytoplasmic tail of ICAM-1 interacts directly
with actin-binding proteins, such as actinin, ezrin, and
moesin (Carpen et al., 1992; Heiska et al., 1998; Barreiro
et al., 2002). In addition, when crosslinked by antibody or
engaged by leukocytes, ICAM-1 can reorganize the actin
cytoskeleton (Amos et al., 2001; Wang et al., 2002) by acting
through a Rho-dependent pathway (Adamson et al., 1999).
Here we show that simple overexpression of ICAM-1 in
cultured human dermal microvascular EC (HDMEC) can
cause vascular leakiness as well as EC shape change,
cytoskeletal reorganization, and junctional protein alterations
in the absence of crosslinking or leukocyte binding. Like
ICAM-1 induction, TNF-induced leakiness and shape change
require NF-kB-induced protein synthesis. However, our
studies using siRNA suggest that even though increased
expression of ICAM-1 contributes to TNF-initiated responses,
it does not wholly account for them.
RESULTS
Effects of ICAM-1 overexpression
Cultured HDMEC grown to confluence on fibronectin-coated
transwell inserts form a monolayer that resists the passage of
electrical current, which may be quantified as a transen-
dothelial electrical resistance (TEER). To examine the effects
of ICAM-1 expression on barrier function, we produced a
series of retrovirally transduced HDMEC cell lines. These
consisted of cell lines that expressed ICAM-1, E-sel, or control
transductants (made with empty viral vector). By FACS
analysis, control transductants expressed ICAM-1 at levels
comparable to basal expression on non-transduced HDMEC,
and are therefore designated as ICAM-1basal. Cell lines that
expressed ICAM-1 at levels comparable to that seen
following TNF are designated as ICAM-1med and cell lines
that expressed approximately 8-fold higher levels are
designated as ICAM-1high. Neither ICAM-1basal, ICAM-1med,
nor ICAM-1high expressed E-sel. E-sel transductants E-sel
expressed E-sel at levels comparable to that observed in TNF-
treated HDMEC, but remained at basal levels for ICAM-1
(Figure 1a). We plated E-sel, ICAM-1basal, and ICAM-1med on
fibronectin-coated transwells and measured TEER on a daily
basis as the cells reached confluence. TEER increased daily,
reaching a plateau of maximal TEER 48–72 hours post-visual
confluence. The level of TEER achieved by ICAM-1med
monolayers was significantly lower than that achieved by
ICAM-1basal or E-sel (shown in Figure 1b, upper panel).
ICAM-1high monolayers established very little TEER, ap-
proaching that of naked transwells (Figure 1b, lower panel).
The effects of different levels of transduced ICAM-1 expres-
sion on TEER were reproducible in three separately derived
sets of transductants, analyzed in multiple independent
experiments.
To determine if the fall in monolayer TEER observed with
increasing ICAM-1 expression by HDMEC represents a
change in macromolecular permeability, we cultured
ICAM-1basal, ICAM-1med, and ICAM-1high HDMEC transduc-
tants on transwells until TEER became maximal and
measured the transmonolayer flux of FITC-tagged BSA. The
flux of FITC-BSA across naked transwells was much greater
than across transwells containing post-confluent HDMEC,
indicating that HDMEC formed a monolayer with barrier
function toward BSA (data not shown). The passage of FITC-
BSA accelerated with increasing levels of HDMEC ICAM-1
expression (Figure 1c), and as reported by others (Marcus and
Gewertz, 1998) the rate of protein flux was inversely
proportional to TEER. These differences in transmonolayer
flux of BSA and in TEER cannot be ascribed to reduced cell
density, as ICAM-1med and ICAMhigh cells reached equivalent
if not greater numbers at 48 hours post-confluence than did
ICAM-1basal or E-sel (data not shown).
The creation of an endothelial barrier has been correlated
with the organization of actin filaments into dense peripheral
bands; vascular leakiness occurs at sites where actin
filaments rearrange into longitudinal stress fibers (Stolpen
et al., 1986; Brett et al., 1989). This reorganization of actin
filaments also results in a change in cell shape from
polygonal to elongated (Wojciak-Stothard et al., 1998). These
observations have been used to infer that a reorganization of
the actin cytoskeleton underlies the development of leaki-
ness. To examine this hypothesis, we quantified cell shape in
confluent monolayers of our transductants by determining
ratios of the longest to the shorter perpendicular axis of
HDMEC (an ‘‘axis ratio’’) from morphometrical measure-
ments, using the staining pattern of the junctional protein
vascular endothelial (VE)-cadherin as a guide. The majority of
ICAM-1high cells were elongated in cell shape relative to
ICAM-1basal controls or E-sel HDMEC (quantified morphome-
trically in Table 1). This difference in ICAM-1high shape could
also be visualized by phalloidin staining as a thickening of
the actin stress fibers (Figure 2a). Importantly, despite lower
TEER relative to ICAMbasal, visible elongation and re-
organization of actin filaments were not observed for
ICAMmed.
As TNF-induced leakiness has been correlated with an
increase in the filamentous (F-) to monomeric (G-) actin ratio
(Wojciak-Stothard et al., 1998), we examined whether this
ratio may be directly affected by ICAM-1. Compared to E-sel,
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the F/G actin ratio is increased nearly 3-fold in ICAMhigh
transductants by immunoblot analysis of lysates obtained by
differential detergent extraction (Figure 2b). However, no
increase in the F/G actin ratio of ICAMmed was observed
relative to that of E-sel or ICAMbasal (in two independent
experiments with two different HDMEC lines; data not
shown). These results suggest that re-organization of the
actin cytoskeleton underlies shape changes we observed at
higher levels of ICAM-1 expression. However, higher levels
of ICAM-1 are required to reorganize the actin cytoskeleton
than are required to reduce TEER.
Two different types of intercellular junctions composed of
different molecular structures normally maintain permselec-
tivity of EC to blood macromolecules, namely tight junctions,
formed by occludin, claudins, junctional adhesion molecules
and associated zona occludens 1 (ZO-1), and adherens
junctions, formed by VE-cadherin and catenins (Stevens
et al., 2000; Bazzoni and Dejana, 2004). As TNF treatment
disrupts the otherwise continuous staining patterns of
junctional molecules like ZO-1 (at tight junctions, Blum
et al., 1997) and VE-cadherin (at adherens junctions;
Wojciak-Stothard et al., 1998; Corada et al., 1999) we
examined whether the distribution patterns of these proteins
might be affected by increased ICAM-1. The immunostaining
patterns for VE-cadherin and ZO-1 were disjoined and fainter
in ICAMhigh compared to E-sel and ICAMmed transductants,
which more closely resembled ICAMbasal (non-transduced)
control HDMEC (Figure 3). Compared with other HDMEC
transductants, VE-cadherin, and ZO-1 immunostaining pat-
terns of ICAMhigh appeared visibly fragmented and inter-
digitized along the paracellular boundaries. We quantified
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Figure 1. Adhesion molecule expression and permeability measurements on HDMEC transductants. (a) Adhesion molecule expression as assessed by direct
immunofluorescence and FACS analysis is presented in histograms plotting fluorescence intensity (logarithmic x axis) versus cell number (y axis).
Immunostaining with anti-ICAM-1 and anti-E-sel (dark lines), isotype-matched control (light lines) and the mean fluorescence intensity (MFI) corrected for
isotype control are shown. (b) TEER properties of HDMEC transductants. TEER measurements on ICAMmed (top) and ICAMhigh (bottom) HDMEC transductants
were recorded daily and compared to those on ICAMbasal (empty vector control transduced) and E-sel HDMEC. TEER levels (y axis) are the mean electrical
resistance in ohms7SEM corrected for the resistance of a naked transwell. *Po0.001 by two-way ANOVA, Bonferroni post-test (n¼ 6, 6, 6). Shown are two out
of a total of five independent experiments involving three separately derived HDMEC lines for each construct. (c) Comparison of TEER with flux of BSA across
transwells of transduced HDMEC monolayers. By FACS analysis HDMEC expressed ICAM-1 at basal, medium, or high levels. After measuring TEER, FITC-tagged
BSA was added to the upper chamber of each transwell. The molar amount of BSA collected from the bottom chamber was used to determine a flux rate based
on the transwell surface area (0.3 cm2) and the duration of the flux assay (20 hours). *Po0.001 by one-way ANOVA, Bonferroni post-test (n¼ 6, 6, 6).
Representative of two independent experiments.
Table 1. Cell shape comparison among HDMEC
transductants
Construct Axis ratio
ICAMbasal 3.270.21
ICAMmed 2.770.17
ICAMhigh 4.570.32*
E-sel 3.170.21
E-sel, E-selectin; HDMEC, human dermal microvascular endothelial cell.
Morphometry units are the mean ratio of the longest axis and
perpendicular short axis7SEM measured on individual HDMEC immu-
nostained for VE-cadherin. *Po0.01 by one-way ANOVA, Dunnett’s
post-test. Representative of three independent experiments with trans-
duced HDMEC derived from two different skin sources, n=50 per group.
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patterns of immunostained junctions using morphometry
software (Image J) according to a method established by
others (Macconi et al., 2006). For two different lines of
ICAMhigh, the number of tight junction-associated ZO-1
segments increased and the length per segment decreased
compared to E-sel control HDMEC (Tables 2 and 3). Again
compared with E-sel, in ICAMmed the number of ZO-1
segments increased and length per segment decreased, but to
a lesser extent than for ICAMhigh (Table 2). However, this
comparison did not reach statistical significance in the
VE-cadherin
ZO-1
ICAMbasal ICAMmed ICAMhighE-sel
ICAMbasal ICAMmed ICAMhighE-sel
Figure 3. Assessment of changes in adherens and tight junctions among HDMEC transductants. The adherens junctions and tight junctions of HDMEC
transductants fixed in ethanol/5% acetic acid were visualized by immunostaining with goat anti-VE-cadherin and mouse anti-ZO-1, respectively. Fragmented
and interdigitized junctional immunostaining of VE-cadherin and ZO-1 in ICAMhigh differed from that of E-sel (arrows) which appeared continuous, more like
that of non-transduced ICAMbasal control HDMEC. Antibody specificity was assessed by pre-adsorbing anti-VE-cadherin with immunogenic peptide before
immunostaining (top left inset) and by comparing anti-ZO-1 with a mouse IgG1 isotype control (bottom left inset). Bar¼10 mm.
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Figure 2. Cytoskeletal re-organization among HDMEC transductants.
(a) Changes in actin cytoskeleton organization among HDMEC transductants
were visually assessed by phalloidin staining of filaments and 40,6-diamidino-
2-phenylindole, dihydrochloride staining of nuclei. The actin cytoskeleton
organization of ICAMbasal, ICAMhigh, ICAMmed, and E-sel HDMEC are shown.
Bar¼10 mm. Representative of three independent experiments using two
separately derived HDMEC lines. (b) Immunoblot analysis of cytoskeleton
re-organization. The bands shown represent the relative amounts of F- and
monomeric G- forms of b-actin, derived from detergent insoluble (insol.) and
detergent soluble (sol.) protein lysates, respectively (see Materials and
Methods), obtained from ICAM-1 and E-sel transductants (left) and non-
transduced HDMEC either treated with vehicle or TNF (10 ng/ml for 24 hours;
right). The F-/G-actin ratio shown below was determined by densitometry for
each HDMEC condition after detection with mouse anti-b-actin mAb.
Representative of three or more independent experiments with three different
lines of transduced HDMEC and four different lines of non-transduced
HDMEC.
Table 2. Morphometric analysis of ZO-1 and VE-
cadherin immunostaining at HDMEC junctions
Antibody Transductant Segments/field
Mean segment
length/field (in
lm)
Anti-ZO-1 ICAMmed 402.2722.4* 2.9670.13**
ICAMhigh 788.8760.3* 1.7770.06*
E-sel (control) 264.4722.2 4.3170.33
Anti-VE-cadherin ICAMmed 657.8724.9* 2.0670.06
E-sel (control) 583.9724.0 2.0470.09
E-sel, E-selectin; HDMEC, human dermal microvascular endothelial cell;
VE, vascular endothelial; ZO-1, zona occludens 1.
For these HDMEC lines derived from the same skin donor, morphometric
analysis of tight junction ZO-1, and adherens junction VE-cadherin
immunostaining was performed after fixing in ethanol/acetic acid (for
detection of intracellular ZO-1) or in paraformaldehyde (for detection of
transmembrane VE-cadherin).
Statistical significance was determined with reference to E-sel control
transductants.
*Po0.05, **Po0.01 by one-way ANOVA, Dunnett’s post-test. *Po0.05
by unpaired t-test.
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second of two ICAMmed lines examined (Table 3). E-sel
measurements were comparable to those of non-transduced
HDMEC by this analysis (data not shown). Extensive re-
distribution of VE-cadherin surface expression away from
intercellular adherens junctions was observed in paraformal-
dehyde-fixed ICAMhigh that prevented evaluation by this
method (data not shown). In ethanol- and acetic acid-fixed
ICAMhigh, however, intracellular, presumably cytoskeleton-
associated VE-cadherin could be evaluated and by this
approach the number of adherens junction-associated VE-
cadherin segments was increased and the segment length
decreased compared to E-sel control HDMEC (Table 3). For
ICAMmed, the number of adherens junction-associated VE-
cadherin segments increased in one of the two lines
examined, but there were no differences measured in
segment length (Tables 2 and 3). These measurements
support visually apparent differences in ICAMhigh ZO-1 and
VE-cadherin immunostaining and suggest that more subtle
junctional differences among ICAMmed and E-sel control are
detectable, but vary among the two lines of transductants
examined.
Our initial hypothesis was that because ICAM-1 interacts
with the actin cytoskeleton through its intracellular region,
increased levels of ICAM-1 expression would perturb the
actin cytoskeleton, affecting cell junctions, and paracellular
permeability. However, the experiments described above
suggest that effects on permeability may be uncoupled from
effects on the cytoskeleton requiring higher levels of ICAM-1
expression. To explore this idea further we generated a
truncated form of ICAM-1 that lacked all but one residue of
the ICAM-1 cytoplasmic domain (ICAMDCyto) and should thus
be incapable of directly interacting with the actin cytoske-
leton. As only a portion of HDMEC expressed ICAMDCyto
above basal levels following our standard transduction
procedure, we isolated this population by FACSort (Figure
S1). In two different lines of transduced HDMEC, TEER was
lower in FACSorted ICAMDCyto than in ICAMbasal and E-sel,
but in each case not as low as in ICAMhigh (Figure 4). These
results suggest that regions outside of the ICAM-1 cytoplas-
mic domain can contribute to vascular leakiness.
Effects of TNF-treatment on ICAM-1 expression, leakiness, and
shape change
As overexpressing ICAM-1 in HDMEC was observed to cause
changes in TEER and cytoskeletal organization resembling
those caused by TNF, we assessed the potential contributions
Table 3. Morphometric analysis of ZO-1 and VE-
cadherin immunostaining at HDMEC junctions
Antibody Transductant Segments/field
Mean segment
length/field
(in lm)
Anti-ZO-1 ICAMmed 561738.4 2.2170.093
ICAMhigh 830725.3* 1.4270.047*
E-sel (control) 488726.5 2.2270.14
Anti-VE-cadherin ICAMmed 9437105.0 1.5470.100
ICAMhigh 1496756.5* 1.4070.057
E-sel (control) 986796.9 1.4770.087
E-sel, E-selectin; HDMEC, human dermal microvascular endothelial cell;
VE, vascular endothelial; ZO-1, zona occludens 1.
Morphometric analysis of ZO-1 and VE-cadherin immunostaining in
transduced HDMEC lines derived from a second, different donor than in
Table 2.
The ZO-1 segment length/field measurement for ICAMmed but not for E-sel
was statistically greater that of non-transduced control HDMEC (Po0.05;
data not shown).
Both tight junction ZO-1 and adherens junction VE-cadherin immunos-
taining was performed after fixing in ethanol/acetic acid.
Statistical significance was determined with reference to E-sel control
transductants.
*Po0.001 by one-way ANOVA, Dunnett’s post-test.
Table 4. Morphometric analysis of shape change of
SRIjB-transduced HDMEC
HDMEC line TNF treatment Cell shape ratio
Vector-transduced  1.870.1
Vector-transduced + 3.770.3*
SRIkB  2.170.1
SRIkB + 1.970.1
HDMEC, human dermal microvascular endothelial cell; SRIkB, mutagen-
ized S32/36A IkBa super repressor of NF-kB.
Assessment of TNF-induced shape change in SRIkB-transduced HDMEC
compared to vector-transduced HDMEC. Morphometry units are the
mean ratio of the longest axis and perpendicular short axis7SEM
measured on individual HDMEC immunostained for VE-cadherin.
Representative of four independent experiments using HDMEC derived
from two different skin sources, n=50 per group.
*Po0.01 versus untreated vector-transduced HDMEC by one-way
ANOVA, Dunnett’s post-test.
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Figure 4. TEER properties of ICAMDCyto HDMEC. TEER measurements were
recorded daily on ICAMDCyto HDMEC and compared to those on vector-
transduced ICAM-1basal, E-sel, and ICAMhigh HDMEC. TEER levels (y axis) are
the mean electrical resistance in ohms7SEM corrected for the resistance of a
naked transwell. *Po0.01 versus ICAMbasal by two-way ANOVA, Bonferroni
post-test, n¼ 5 per transductant. Representative of a total of six independent
experiments involving two differently derived HDMEC ICAMDCyto
transductants.
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of ICAM-1 to TNF-induced leakiness by comparing the
quantitative and kinetic relationships of TNF-induced ICAM-1
expression to TNF-induced changes in TEER and shape. We
first added 10 ng/ml TNF to a confluent HDMEC monolayer
and followed the effect on ICAM-1 expression over time.
TNF-treated HDMEC showed no change in their basal
expression level of ICAM-1 for at least 1 hour, markedly
increased their expression level at 4 hours and even further
increased their expression level at 24 hours (Figure 5a). In
replicate TNF-treated HDMEC cultures we observed that the
time dependence of the TEER response was similar to that
observed for induction of ICAM-1 expression; TEER was
sustained for at least 1 hour before decreasing at 4 hours, and
falling even further by 24 hours, compared to a vehicle-
treated monolayer (Figure 5b). The time dependence of the
TNF-induced HDMEC elongation response was somewhat
slower than those of ICAM-1 expression or TEER, not
changing during the first 4 hours but visually apparent at
24 hours (Figure 5c). TNF-treated HDMEC that had under-
gone shape change also showed a 6-fold increase in actin
polymerization (Figure 2b). We then compared the HDMEC
response of TNF to that of thrombin, an agent known to
cause rapid increases in vascular permeability. In contrast
to the TNF response, thrombin caused a fall of TEER within
10 minutes that returned to baseline by 24 hours (Figure 5b).
Moreover, unlike TNF, thrombin did not increase expression
of ICAM-1 or change HDMEC shape, further emphasizing
that differing mechanisms underlie the actions of these two
inflammatory mediators (data not shown).
We next examined the concentration dependence of these
three responses at 48 hours of TNF treatment. Pilot experi-
ments established that all three TNF-induced changes were
maximal at 10 ng/ml. A 50% maximal change in ICAM-1
expression and in cell elongation each occurred at 1.1 ng/ml
TNF. In contrast, only 0.13 ng/ml was required to produce a
50% of maximum fall in TEER (Figure 5d–f). Collectively,
these data suggest that while increased ICAM-1 expression
may contribute to TNF-induced leakiness, it does not wholly
account for it.
Contributions of increased ICAM-1 expression to TNF-induced
leakiness and shape change
To more directly assess the contributions of ICAM-1 to TNF-
induced leakiness and EC shape change, we pursued two
parallel strategies. First, we blocked ICAM-1 induction by
interference with TNF-induced gene transcription. Many
TNF-induced transcriptional events in EC, including that of
ICAM-1, are controlled by NF-kB activation, which is
repressed by IkBa in the absence of TNF (Collins et al.,
1995). TNF-mediated NF-kB activation can be blocked by
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Figure 5. HDMEC responses to TNF. (a–c) Time dependence of HDMEC TNF responses. (a) FACS analysis of ICAM-1 expression through 24 hours of TNF
quantified as the isotype-corrected MFI of anti-ICAM-1-FITC immunostaining (logarithmic y axis). (b) TEER measurements of TNF-induced leakiness. TEER
was reduced at 4 hours of TNF (10 ng/ml) versus at 10 minutes of thrombin (2 NIH U/ml). The cytokine-induced fall in TEER is expressed as the percentage
different from TEER of vehicle-treated control HDMEC (percent change, y axis; described in Materials and Methods).**Po0.001 for TNF (n¼ 6) versus control
(n¼5), *Po0.001 for Thrombin (n¼6) versus control by two-way ANOVA, Bonferroni post-test. Representative of three independent experiments with
similar results. (c) Quantitative morphometry of TNF-induced shape change. TNF-induced shape change was delayed, first detected after 4 hours of TNF
treatment. Replicate monolayers of untreated HDMEC showed no change in shape over the same period (data not shown). *Po0.01 versus baseline (pre-TNF
treatment); NS, not significant by one-way ANOVA, Bonferroni post-test. Representative of three independent experiments. (d–f) Concentration dependence
of TNF responses. (d) By FACS analysis, ICAM-1 expression increased as a function of TNF concentration, reaching 50% of the measured change at 1.1 ng/ml
TNF. (e) TEER was reduced by 50% at 0.13 ng/ml TNF, an approximately 10-fold less concentration than that required for a 50% increase in ICAM-1 expression
or cell shape. The TNF-induced fall in TEER was calculated relative to the TEER of vehicle-treated HDMEC as in Figure 5b, except is expressed as a positive
value for comparison with the HDMEC ICAM-1 and shape responses to TNF (percent reduction, y axis) (f) By morphometry, HDMEC shape elongated
50% at a TNF concentration of 1.1 ng/ml. Data in (d–f) are representative of two independent experiments with HDMEC obtained from different skin sources.
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overexpression of a mutagenized S32/36A IkBa that acts as a
‘‘super repressor’’, designated SRIkB. Compared to enhanced
green fluorescent protein transductants, SRIkB-HDMEC
showed reduced nuclear translocation of Rel A (also known
as the p65 subunit of NF-kB) in response to TNF (data not
shown) and reduced (but did not eliminate) basal and
inducible expression of ICAM-1 (Figure S2). Strikingly,
SRIkB-transduced HDMEC did not lose TEER in response to
TNF (through 48 hours) despite retaining a rapid TEER loss in
response to thrombin (Figure 6). TNF also failed to induce
shape change in SRIkB-transduced HDMEC derived from two
different skin sources (quantified in Table 4) an inhibition that
was clearly visible at the level of the actin cytoskeleton (data
not shown). These data show that TNF-induced TEER loss and
shape change require NF-kB inducible protein expression in
HDMEC, but they do not directly link ICAM-1 to this process.
Our second strategy to connect ICAM-1 to TNF-mediated
responses involved the use of siRNA to specifically reduce
ICAM-1 expression. We analyzed four different siRNA
sequences specific to ICAM-1 and compared our results to
an irrelevant siRNA (nuclear lamin A; siRNA sequences are
listed in Table S1). Unfortunately, the oligofectamine-based
transfection procedure itself caused a significant fall in TEER
making it impossible to unambiguously assign effects to
specific siRNA molecules with this assay. However, transfec-
tion did not alter cell shape. In this case, three different siRNA
sequences that reduced ICAM-1 expression (without affecting
E-sel; data not shown) did reduce the extent of cell elongation
caused by TNF (Table 5). However, the magnitude of the
effects on ICAM-1 expression and cell elongation did not
strictly correlate. This was evident with siRNA 731 which
could reduce the level of ICAM-1 surface expression without
blocking shape change. These data support a role for ICAM-1
in mediating the TNF effects on the HDMEC cytoskeleton, but
indicate that other proteins requiring NF-kB activation for
their TNF-inducible expression are also involved in this
response.
DISCUSSION
We hypothesized that induction of ICAM-1 can cause
leakiness in HDMEC monolayers and present data showing
that retrovirally transduced ICAM-1 causes reduced TEER and
overt alterations to the actin cytoskeleton and endothelial
junctions. Compared to ICAMbasal control and E-sel, leak was
increased at TNF-inducible levels of ICAM-1 expression
(ICAMmed), measured as a significant (425%) fall in TEER
and a doubling of the transmonolayer flux rate of FITC-BSA
(Figure 1). At high levels of ICAM-1 expression, thickening of
the actin stress fibers was visibly apparent (Figure 2). More-
over, this change was correlated with a transition from the
detergent soluble to the detergent insoluble fraction that we
measured as an increased F/G actin ratio. High levels of
ICAM-1 expression also produced quantifiable gaps in ZO-1
and VE-cadherin immunostaining (Figure 3 and Tables 3 and
4). Finally, we show that the effects of ICAM-1 over-
expression on TEER and the actin cytoskeleton reside, at
least in part, outside of the ICAM-1 cytoplasmic tail (Figure 4).
The ability of ICAMDCyto to reduce TEER was unexpected.
Such effects are presumably mediated by interactions of the
extracellular and/or transmembrane regions of ICAM-1 with
other membrane proteins. Possible interactive targets include
junctional proteins and/or other transmembrane proteins
(including full-length endogenous ICAM-1) that couple to
the cytoskeleton. The effect of ICAMDCyto on actin re-
organization was variable (data not shown). Although we
did not directly compare ICAMDCyto expression among
different transductants, our data would suggest that such
differences (like those of ICAMmed on endothelial junctions)
may derive from differences in the level of ICAM-1 expressed.
We have been unable to assess the effect of overexpressing
the ICAM-1 cytoplasmic domain directly. A chimeric
construct consisting of the ICAM-1 cytoplasmic domain
linked to the extracellular and transmembrane domains of
E-sel, showed TEER equivalent to that of ICAMbasal, but
because expression levels were consistently and considerably
less than that of ICAMmed, it was not possible to definitively
assess the role of the ICAM-1 cytoplasmic domain. Experi-
ments using dominant-negative peptides based on the ICAM-
1 cytoplasmic domain have been inconsistent (unpublished
observations, MSK).
An important message of these studies is that leakiness
does not appear to require major cytoskeleton-based changes
in cell shape or major alterations in junctional protein
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Figure 6. Responses of SRIjB- and enhanced green fluorescent protein-
transduced HDMEC to TNF. TNF-induced leakiness is blocked in SRIkB
HDMEC. Leakiness in response to either 10 ng/ml TNF (top) or 2 NIH U/ml
thrombin (bottom) is expressed as a percent of TEER measured on vehicle-
treated replicate cultures (y axis) *Po0.01 by two-way ANOVA, Bonferroni
post-test. Representative of three independent experiments and HDMEC
obtained from two different skin sources.
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organization. This conclusion is based upon differences in
ICAM-1 (and TNF) levels needed to change these parameters
(Table 1 and Figures 2a, 5e and f), and upon different time
courses of TNF needed for their occurrence (Figure 5b and c).
And based on examination and analysis of cell–cell junctions,
leakiness does not appear to require major alterations to
junctional protein organization (Figure 3; Tables 2 and 3).
The observed differences suggest either that barrier function
can be regulated independently from the cytoskeleton, or that
a greater signal strength, operating through the same
mechanism, is necessary for evoking shape change than
vascular leak. In other words, our data do not rule out the
possibility that the actin cytoskeleton could be a common
mediator of both responses, potentially altering junctional
proteins in a manner not detectable by the assays used in this
study.
Having established that ICAM-1 expression can cause
vascular leak, we then investigated whether increased
expression of ICAM-1 contributes to the development of
vascular leak in response to the proinflammatory cytokine
TNF. Our most direct observations in support of this concept
are that HDMEC expressing levels of ICAM-1, but not of E-sel,
comparable to those induced by TNF show both a loss of
TEER and an increase in the passage of BSA proportional to
their level of ICAM-1 expression. Transduction of ICAM-1
also produced visible changes in the actin cytoskeleton,
measured as an elongation in cell shape, and an increased
F/G actin ratio, that were quantitatively similar to those seen in
TNF-treated cells. The contribution of ICAM-1 to the effects
of TNF on TEER was further supported by the ability of SRIkB,
a super repressor of NF-kB activation, to block both TNF
induction of ICAM-1 expression and TNF reduction of TEER.
However, ICAM-1 is likely to account only partially for the
effect of TNF on TEER, because TEER was reduced at lower
TNF concentrations than were needed to induce ICAM-1
expression. TNF-induced shape change also was reduced by
specific siRNA knockdown of ICAM-1 expression. However,
once again, this activity of ICAM-1 is likely to account only
partially for the effect of TNF, as an equivalent shape change
required higher levels of ICAM-1 in transductants than in
TNF-treated HDMEC, and because the effects of siRNA
knockdown of ICAM-1 expression were not fully concordant
with effects on cell shape. Our approaches taken to reduce
ICAM-1 expression or effects have limitations. Our SRIkB
HDMEC are fully refractory to TNF-induced permeability,
consistent with a contributory role for ICAM-1 in TNF-
induced leak, but this approach inhibited TNF-induced
synthesis of many proteins in addition to ICAM-1. SiRNA
experiments, which are more specific to ICAM-1, may be
complicated by unpredictable off-target effects (the siRNA
Table 5. Effect of siRNA knockdown on EC shape
Experiment Condition
ICAM-1
expression (MFI
corrected for
isotype control)
Cell shape (axis
ratio)
Percentage
siRNA
knockdown of
TNF-induced
ICAM-1
expression1
Percentage
siRNA-
dependent
inhibition of
TNF-induced
shape change2
Two-tailed
unpaired t-test
for shape change
after TNF versus
TNF+siRNA
One No TNF 32 1.8 — — —
TNF 1,308 3.3 — — —
TNF+741 233 2.1 84.2 80.0 Po0.0001
Two No TNF 46 1.8 — — —
TNF 1,685 3.1 — — —
TNF+741 358 2.3 81.0 61.5 Po0.003
TNF+lamin 1,903 3.3 13.3 15.4 NS
Three No TNF 19 1.8 — — —
TNF 1,502 2.5 — — —
TNF+756 302 1.9 80.9 85.7 Po0.03
TNF+749 471 1.7 69.5 114.3 Po0.005
TNF+731 600 2.5 60.8 0.0 NS
TNF+lamin 1,728 2.5 15.2 0.0 NS
EC, endothelial cell; NS, not significant; siRNA, small-interfering RNA; TNF, tumor necrosis factor.
1The siRNA knockdown of TNF-induced ICAM-1 expression is expressed as a percentage of TNF-induced ICAM-1 expression: [((corrected MFITNF –
corrected MFINo TNF) – (corrected MFITNF+siRNA – corrected MFINo TNF))/(corrected MFITNF – corrected MFINo TNF)] 100.
2The siRNA-dependent inhibition of TNF-induced shape change is expressed as a percentage of TNF-induced shape change: [((EC shapeTNF – EC shapeNo
TNF) – (EC shapeTNF+siRNA – EC shapeNo TNF))/(EC shapeTNF – EC shapeNo TNF)] 100.
www.jidonline.org 769
PR Clark et al.
ICAM-1 Causes EC Leak and Shape Change
oligomer that knocked down ICAM-1 without affecting shape
change may have induced a compensatory off target effect
that went undetected). We addressed this by using four
different sequences that were screened to rule out strong
induction of interferon-related genes. Despite these limita-
tions, the similar outcome from these different approaches
strengthens our primary conclusion, namely that increasing
ICAM-1 expression induces vascular leak and shape change.
Additionally, these data suggest that in the context of EC
activation by TNF treatment, increased ICAM-1 expression
may contribute to the effects of TNF on vascular leak through
cytoskeletal re-organization.
It is clear from our studies that changes in TEER and
HDMEC shape following TNF require new, NF-kB-dependent
protein synthesis. In this regard our data differ from a recent
study in which reduction of TEER by TNF required ezrin/
radixin/moesin phosphorylation, detected before induction of
ICAM-1 expression by TNF (Koss et al., 2006). Our data also
differ from another study that reported rapid, rho-dependent
responses to TNF in HUVEC (Wojciak-Stothard et al., 1999).
Factors that may explain these differences are that we used a
different EC type, namely HDMEC, that form an effective
barrier to passage of electrical current, and that our transwell
measurements were not performed until maximal levels of
TEER were reached at 48–96 hours post-confluence. It will be
important to investigate whether or not changes in EC
permeability owing to ICAM-1 occur independently from
changes owing to TNF-induced ezrin/radixin/moesin phos-
phorylation or Rho activation. Our data suggest that the
mechanism and speed of these TNF effects differ from that of
thrombin, a trimeric G-protein coupled receptor ligand that
acts in minutes and is not affected by blocking NF-kB. We
also believe that previously described inhibitory effects of
pertussis toxin on TNF-induced leakiness (Brett et al., 1989)
may be better explained by the elevation in cAMP produced
by pertussis toxin than by any direct effect on TNF signaling.
Previous reports have shown that adenoviral transduction
of EC with SR-IkB render EC sensitive to TNF-mediated
apoptosis (Ferran et al., 1998; Deshpande et al., 2000). We
did not observe this in our experiments. TNF-treated SRIkB-
HDMEC were fully resistant to substrate-detachment as
assessed by phase microscopy, to nuclear condensation,
and fragmentation by fluorescence microscopy of 40,6-
diamidino-2-phenylindole, dihydrochloride staining, and to
loss of membrane integrity by propidium iodide dye
exclusion (unpublished observations, PRC and MSK). A
possible explanation for their escape from apoptosis is that
blockade of NF-kB activation was incomplete, either owing
to a lower level of SR-IkB achieved with retroviral transduc-
tion than with adenovirus transduction or plasmid transfec-
tion, or owing to use of a mouse rather than a human SRIkB
construct. Indeed, we did not see total inhibition of ICAM-1
expression (Figure S2), nor did we see a complete loss of
cellular FADD-like IL-1b-converting enzyme-inhibitory pro-
tein (c-FLIP) expression (unpublished observations, MSK and
PRC), a key NF-kB-dependent antiapoptotic protein. It has
been reported that post-confluent HUVEC expressing SRIkB
can resist apoptosis after TNF treatment (Cota-Gomez et al.,
2002) and that VEGF can promote EC survival under
confluent conditions (Spyridopoulos et al., 1997; Carmeliet
et al., 1999; Grazia Lampugnani et al., 2003). Thus, either
VEGF present in the growth medium or our use of post-
confluent HDMEC may have counter-balanced the TNF
signal for apoptosis as well. Whatever the explanation, our
data suggest targeting endothelial NF-kB is a potential anti-
inflammatory therapy so long as blockade is incomplete.
A final point of discussion is that our in vitro experiments
do not take into account the possible contributions of
leukocytes to vascular leak. We noted that ICAM-1 knockout
mice show less leakiness at sites of inflammation in contact
sensitivity responses (Sligh et al., 1993; Xu et al., 1994). This
may well result from the absence of ICAM-1-stimulated
leukocyte activation rather than (or in addition to) its role
within EC. Indeed, many of the previous studies linking NF-
kB to vascular leak are better explained as effects on protein
(e.g., cytokine) synthesis by leukocytes rather than on EC
effects (Moine et al., 2000; Gautam et al., 2001; Lentsch and
Ward, 2001). However, these studies do not rule out a role
for activation of NF-kB in EC. For example, exogenous
administration of secretory leukocyte protease inhibitor, a
naturally occurring NF-kB inhibitor expressed by EC, inhibits
vascular leak in vivo and attenuates pulmonary vascular
expression of ICAM-1 without affecting macrophage NF-kB
(Lentsch et al., 1999; Lentsch and Ward, 2001). Moreover,
leak can occur without leukocytes present, for example in
settings of neutropenia (Ognibene et al., 1986). More
pertinent to this study, leukocyte ligand engagement may
induce ICAM-1 oligomerization, contributing to ICAM-1-
mediated signaling by clustering endothelial ICAM-1 mole-
cules (Wojciak-Stothard et al., 1999; Barreiro et al., 2002).
However, it is possible that at sufficiently high levels of
expression, ICAM-1 may spontaneously oligomerize on EC
and signal without leukocyte engagement (Yang et al., 2004)
and like TNF receptors that are normally activated by ligand-
induced clustering (Gaeta et al., 2000), may spontaneously
signal when simply overexpressed in EC. Leukocyte-inde-
pendent clustering may potentially explain why the responses
we observed with ICAM-1 transduction in vitro without
leukocytes present required higher concentrations of ICAM-1
than are necessary in vivo, and if clustering does underlie the
fall in TEER at high levels of ICAM-1 expression, then it
would be expected to occur in ICAMDCyto, which retains both
of the extracellular domains believed to promote dimeriza-
tion (Yang et al., 2004).
In conclusion, we have presented evidence that increased
ICAM-1 expression on HDMEC can mediate vascular leak
and cell shape change, a putative means of coordinating
leakiness with leukocyte recruitment. However, our data also
suggest that while increased ICAM-1 expression may underlie
some of the EC effects of TNF, it is unlikely to be the only
TNF-induced protein that contributes to such changes.
MATERIALS AND METHODS
Reagents
TNF was obtained from R&D Systems (TNFa, Minneapolis, MN) and
recombinant bovine thrombin from Amersham Biosciences Corp
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(Piscataway, NJ). Unless specified, all other reagents were from
Sigma-Aldrich Corp. (St Louis, MO).
HDMEC cultures
All human materials were obtained with patient consent and in
compliance with the Declaration of Helsinki Principles under
protocols approved by the Yale Human Investigations Committee.
HDMEC were liberated from the superficial vascular plexus of
the upper dermal layers of normal adult human skin obtained
from discarded surgical specimens by dermatome, followed by
digestion with Dispase (50 U/ml; BD Biosciences, San Jose, CA)
for 30 minutes at 371C and fine mincing as described previously
(Kluger et al., 1997). Released cells were cultured on 10 mg/ml
human plasma fibronectin-coated plastic (Falcon, Lincoln Park, NJ)
in EGM2-MV growth medium (Cambrex; East Rutherford, NJ).
After 5–7 days in primary culture substrate-adherent cells were
resuspended using trypsin and immunoselected on a mini-magnetic-
activated cell sorter column using anti-CD-31-biotin followed
by streptavidin-magnetic beads (Miltenyi Biotec, Auburn, CA).
Immunoselected HDMEC were serially passaged on 0.1%
gelatin-coated plastic and 499% free of contaminating leukocytes
as assessed by immunohistochemistry and FACS analysis. In
response to TNF, HDMEC uniformly upregulate ICAM-1 and
VCAM-1 and express E-sel. The majority of the cells concomitantly
express both venular (E-sel/CD62E, CD34) and lymphatic
(podoplanin, Prox-1) markers. Confluent HDMEC monolayers
develop well-formed inter-EC contacts that stain with mouse
anti-human PECAM-1 (CD31) antibody (DAKO, Carpinteria, CA)
adherens junctions that stain with goat anti-human VE-cadherin
(CD144) antibody (Santa Cruz Biotechnology, Santa Cruz, CA),
and tight junctions that stain with mouse anti-human ZO-1 (Zymed
Laboratories, Inc., San Francisco, CA), features of blood vascular
EC. As a result, HDMEC monolayers attain higher levels of
TEER than HUVEC, which unlike cultured blood microvascular
EC, lack tight junctions (Blum et al., 1997). HDMEC were
used between passage four through eight for the experiments
described.
Retroviral transduction of HDMEC
Inserts for the translated region of human adhesion molecules ICAM-
1 (gift of D. Altieri, University of Massachusetts Medical School,
Worcester, MA) and human E-sel (Kluger et al., 2002) were ligated
between the long terminal repeat regions of the retroviral vector
pLZRS immediately downstream of an inserted cytomegalovirus
promoter (used in ICAMmed and E-sel HDMEC), or into the same
vector without the cytomegalovirus promoter (used to generate
ICAMhigh HDMEC). A truncated ICAM-1 insert, missing a cytoplas-
mic domain except for the first, most membrane proximal Arg
residue (ICAMDCyto) was obtained by PCR and ligated into pLZRS.
Identities of all constructs were confirmed by sequencing (a
nucleotide mismatch was detected in the transmembrane domain
of ICAMDCyto resulting in a conservative Leu502Val substitution) and
immunoblotting. The pLZRS vector containing a cytomegalovirus
promoter but minus any insert served as a negative control to
transduce HDMEC. In NF-kB inhibition experiments, either the
cDNA for the mouse S32/36A mutant IkBa super repressor of NF-kB
(SRIkBa; gift of W. Min, Yale University School of Medicine) or
enhanced green fluorescent protein control cDNA (Clontech
Laboratories, Inc., Mountain View, CA) was inserted between the
long terminal repeat regions of the pBMN.neo retroviral vector (gift
of A. Bothwell, Yale University School of Medicine). A second
HDMEC line transduced with the SRIkBa super repressor inserted
into pLZRS with a cytomegalovirus promoter was compared to
negative control consisting of vector without any insert. Retroviral
supernatants produced by transfecting and selecting Phoenix
packaging cells, were used for transducing HDMEC without
selection (Kluger et al., 2002) or (for the pBMN constructs only)
with 1 mg/ml G418 selection (Invitrogen, Carlsbad, CA).
FACS analysis
Expression of ICAM-1 and E-sel on cultured HDMEC resuspended by
trypsinization were determined by FACS analysis (FACSort, BD
Biosciences) using CellQuestPro after immunostaining with saturat-
ing concentrations of mAbs, either anti-ICAM-1(CD54-FITC, Beck-
man-Coulter Inc., Fullerton, CA), anti-E-sel (CD62E-FITC; R&D
Systems) or with isotype-matched FITC-labeled control antibodies.
Adhesion molecule expression on HDMEC transduced with
pBMN.neo retroviral vectors was determined by two-step immunos-
taining with mouse monoclonal primary antibodies R6.5 (anti-ICAM-
1, gift of Boehringer-Ingelheim Pharmaceuticals Inc.), H 4/18 (anti-E-
sel; Pober et al., 1986a) or isotype-matched control antibodies
followed by phycoerythrin-conjugated F(ab0)2 donkey anti-mouse
secondary antibody (Jackson Labs, West Grove, PA) and FACS
analysis with compensation for enhanced green fluorescent protein-
generated fluorescence when needed. FACSorting was performed on
a Becton Dickinson FACS Aria equipped with Becton Dickinson
FACS Diva Version 4.1.2.
Measurement of TEER and transmonolayer flux of BSA
HDMEC were plated at 50% confluence onto 0.3 cm2 human
plasma fibronectin-coated (10 mg/ml) transwell inserts (BD Bios-
ciences) and fed every 48 hours until formed into a tight monolayer.
At 5 or more days, corresponding to 48–96 hours post-visual
confluence, TEER measurements made daily with a transepithelial
voltohmmeter (World Precision Instruments, Sarasota, FL) stabilized
at 110–150O. Four to six replicate wells were measured per
treatment condition. All TEER values reported were corrected by
subtracting the resistance of a naked transwell (typically 50O).
HDMEC were cultured to X48 hours post-confluence before
addition of cytokine to upper and lower transwell chambers in
experiments involving cytokine. The TNF-induced change in TEER
expressed as a percentage of TEER measurements taken at identical
time points on replicate cultures of vehicle-treated control HDMEC
was computed as: ((TEERTNF/TEERVehicle 100)100). Flux of FITC-
BSA (1 mg/ml) across HDMEC monolayers that had reached peak
levels of TEER was measured by quantifying the fluorescence
(excitation 485 nm, emission 530 nm) of medium collected from
individual transwell bottom chambers with a CytoFluor II fluores-
cence plate reader (PerSeptive Biosystems, Framingham, MA).
Values measured were corrected for background by subtracting the
fluorescence of fresh medium and interpolated relative to a standard
curve derived from graduated FITC-BSA concentrations.
Microscopy and morphometry
Confluent HDMEC monolayers on gelatin-coated cell culture plastic
were washed twice in phosphate-buffered saline (PBS) containing
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Caþ þ and Mgþ þ , fixed in 4% paraformaldehyde/PBS 30 minutes at
room temperature (for cell shape measurements) and blocked
overnight in 0.1% saponin, 5% donkey serum, 1% BSA in PBS at
41C. For morphometric determination of HDMEC shape, cell borders
were labeled by immunostaining with goat anti-human VE cadherin
(sc-6458; Santa Cruz Biotechnology) overnight at 41C followed by
donkey anti-goat Alexafluor 594 or 488 with 40,6-diamidino-2-
phenylindole, dihydrochloride (Molecular Probes, Carlsbad, CA) for
1 hour at room temperature. The same procedure, but with
phalloidin-594 (also Molecular Probes) diluted 1:60 in buffer was
followed for visualization of the actin cytoskeleton in HDMEC
grown on human plasma fibronectin-coated glass cover slips.
Fluorescence images, digitally captured with a Zeiss Axiovert
200M microscope networked to a Macintosh G4 computer using
OpenLab software, version 4.0.3, were morphometrically analyzed
by ImageJ 1.32 software (http://rsb.info.nih.gov/ij/). Cell shape,
specifically the degree of elongation relative to a perfect circle,
was measured in a blinded manner as an axis ratio (also termed
‘‘aspect ratio’’), defined as the ratio of the maximally long cell axis to
a bisecting, perpendicular axis, as performed by others (Yu et al.,
1997; Wojciak-Stothard and Ridley, 2003). The patterns of ZO-1 and
VE-cadherin distribution on HDMEC monolayers fixed in 95%
ethanol/5% acetic acid and immunostained as described above were
measured on 6–16 high power ( 63 objective) fields per transduc-
tant using ImageJ 1.32 (Macconi et al., 2006).
Quantification of F- and G-actin by immunoblot analysis
Confluent monolayers of wild-type (treated7TNF for 24 hours) or
transduced HDMEC lines were washed at room temperature with
1 PBS containing 1mg/ml phalloidin (Sigma) to prevent filament
disassembly, and soluble G-actin was extracted from the cells with
actin extraction buffer I (1 PBS/1% Triton X-100/2 mg/ml phalloi-
din) for 2 minutes as described (Cramer et al., 2002). Lysates were
collected and the monolayers were washed three more times.
Insoluble F-actin was extracted with Actin Extraction Buffer II (1
PBS/1% Triton X-100/2% SDS). Extracted protein lysates were
resolved by SDS-PAGE and proteins were transferred to Immobi-
lon-P polyvinylidene fluoride (Millipore, Bedford, MA). After
blocking in 5% non-fat milk (Bio-Rad, Hercules, CA), b-actin was
detected on the membrane using mouse anti-human b-actin mAb
(Sigma: Clone AC-74). Band intensity was quantified using a
Molecular Dynamics Densitometer and MD ImageQuant v3.31
software.
SiRNA knockdown
HDMEC were plated on to gelatin-coated 12-well plates at
approximately 50% confluence. Mixtures of Oligofectamine to
20 ml/ml and siRNA to 50 nM were prepared in Opti-MEM I Reduced
Serum Medium (all from Invitrogen). At 24 hours post-plating,
concentrated mixtures of siRNA complexes (Dharmacon Inc.,
Chicago, IL) were diluted 5-fold to a siRNA concentration of 10 nM
before co-incubation with HDMEC cultures for 6 hours at 371C.
Fresh medium was added overnight and cells were re-transfected
24 hours later, rested for 24 hours, and then treated with 10 ng/ml
human TNF for 24 hours before morphometric analysis or immu-
nostaining followed by FACS analysis. The four siRNA used to
specifically target ICAM-1 (Vickers et al., 2003) did not inhibit TNF-
induced expression of E-sel (data not shown).
Statistical analysis
Significance of differences among two groups was tested by an
unpaired t-test and among more than two groups, by one-way
analysis of variance (ANOVA) followed by the Dunnet’s post-test in
single variable experiments, or by two-way ANOVA followed by the
Bonferroni post-test in two variable experiments. P-values o0.05
were accepted as significant. All results were computed using Prism
version 4.0c and are presented as means7SEM. A sigmoid curve
nonlinear fit analysis was used to describe the concentration
dependence of TNF-induced changes in ICAM-1 expression,
leakiness, and shape measured on replicate cultures.
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